Market news

Nektar Therapeutics (NasdaqCM:NKTR) plans three oral presentations on rezpegaldesleukin at the European Academy of Dermatology & Venereology Congress 2026. The talks will share 6‑month off‑treatment durability data from the Phase 2b REZOLVE-AA trial in severe alopecia areata. Multi‑omic biomarker findings from atopic dermatitis patients on rezpegaldesleukin are also scheduled for presentation at EADV 2026. The new rezpegaldesleukin durability and biomarker readouts come in addition to a...

Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.

(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK

A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Million Judgment Against Eli Lilly The lawsuit, filed in August 2023, stemmed from a previous licensing agreement between the two companies for the development and commercialization of the drug rezpegaldesleukin. Jury Finds Breach of Covenant The trial in the U.S

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) shares rose 3.6% in premarket trading Friday following a jury verdict awarding the company $90 million in damages in a contract dispute with Eli Lilly and Company (NYSE:LLY).

Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common stock and 5,000 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan.

On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 trials for two separate autoimmune conditions, atopic dermatitis and alopecia areata. Management framed the quarter around two numbers that matter […]

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis (AD). The publication in The Lancet, a world-leading medical journal, provides the medical and scientific community with the full reporting of efficacy, safety, pharmacodynamics, pharmacokinetics, and biomarker

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Nektar Therapeutics (NKTR) shares are in focus after the company reported second quarter 2026 results, with revenue of US$10.13 million and a net loss of US$40.62 million, alongside an earnings surprise relative to analyst expectations. See our latest analysis for Nektar Therapeutics. Nektar Therapeutics shares have eased in the very short term, with a 1-day share price return of 3.82% and a 7-day share price return of 4.52%. However, the stock still shows strong momentum with a year to date...

Nektar Therapeutics stock has delivered a very large gain over the past three years, yet the company now screens as expensive on broad valuation checks. After such a strong run, investors are facing a disconnect between past returns and what the current pricing suggests about future reward for risk. Nektar Therapeutics has returned almost 7x over the past three years, which raises the bar for any further upside from today's price. The launch of late stage trials for rezpegaldesleukin can...

NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.

Moby summary of Nektar Therapeutics's Q2 2026 earnings call

Nektar Therapeutics (NASDAQ:NKTR) said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting w

Nektar (NKTR) delivered earnings and revenue surprises of +40.29% and -6.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) reported a Q2 loss late Thursday of $1.23 per diluted share, narrowing fr

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, with a third study set to start in September. Shares rise.

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the initiation of the first two global registrational trials (ZENITH AD-1 and ZENITH AD-2) in the Phase 3 ZENITH AD program for rezpegaldesleukin. The ZENITH AD program is evaluating rezpegaldesleukin in patients who are 12 years of age or older with moderate-to-severe atopic dermatitis. The program includes three global, randomized, double-blind, place